Neurology

Improved treatment options for patients with relapsing-remitting multiple sclerosis and primary progressive multiple sclerosis.

Investigators identify factors that contribute to the chronic nature of autoimmune diseases.

Top news of the day from across the health care landscape.

A 30% increase in hemoglobin caused the brain to shrink in patients with multiple sclerosis by 0.1%.

Brain shrinkage in patients with multiple sclerosis may be linked to leaked hemoglobin protein.

Babies born with low levels of vitamin D face an increased risk of developing MS in the future.

The FDA has extended the Prescription Drug User Fee Act date for the Biologics License Application review of Roche’s Ocrevus (ocrelizumab) to March 28, 2017.

Patients with serious illness who receive palliative care were more satisfied with their health care.

Patients share their personal stories with Specialty Pharmacy Times.

Ocrelizumab achieves primary endpoints treating primary progressive multiple sclerosis.

Ocrevus is an investigational, humanized monoclonal antibody that may improve multiple sclerosis treatment.

FDA extends biologics license application review for MS drug ocrelizumab (Ocrevus) to allow for more information on manufacturing process.

ICER seeks comment on the effectiveness and value of disease modifying therapies for relapsing remitting and primary progressive multiple sclerosis.

ICER seeks data on the effectiveness and value of disease modifying therapies for relapsing remitting and primary progressive multiple sclerosis.

Ultraviolet light may improve research into multiple sclerosis immune response and allow for the treatment of inflammatory diseases that spares healthy tissue.

Managing fatigue is a significant burden in multiple sclerosis.

Wellness initiatives may help multiple sclerosis patients better manage symptoms of the disease.

Daniel Reich, MD, PhD, won the 2015 Barancik Prize for Innovation in Multiple Sclerosis Research.

Variants of GAL are more common among women, which may explain the high prevalence of multiple sclerosis.

Naturally-occurring genetic variants may improve autoimmune disease treatment.

Individuals diagnosed with multiple sclerosis later in life had progressed towards disability quickly.

Patients who do not respond to interferon-beta treatment for multiple sclerosis have upregulated levels of certain genes.

There is building consensus that multiple sclerosis and rheumatoid arthritis display similar autoimmune genetic pathways.

Gilenya may cause an increase in CD56+-expressing T cells, which can cause MS relapse.

Patients at high risk of early discontinuation of Betaferon should receive consistent care from physicians.